Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Medizone/OTC: MZEI (AIDS and Hepatitis B Treatment) -- Ignore unavailable to you. Want to Upgrade?

To: gtoland who wrote (765)	5/23/2000 11:02:00 PM
From: gtoland	Read Replies (1) \| Respond to of 783

This is great NEWS for those with Hep C.... While outside the auspices of the United States FDA, and conducted without a blind control group, the success obtained by practitioners at the William Hitt Center in treating hepatitis C with ozone has been extremely encouraging. In a sampling of test results from 8 patients, in which post treatment follow-up information was available, viral loads by Polymerase Chain Reaction, taken at the onset of ozone therapy, then repeated following completion of the therapy were compared. An average viral load reduction of 5 log, or 99.96% was achieved. At the onset of treatment seven of the eight patients also had elevated liver enzyme levels as measured by SGOT and SGPT. Following ozone therapy all of the SGOT (AST) U/L and SGPT (ALT) U/L measures fell into the normal range. This pilot trial without a blind control group, conducted in an off shore setting, must be viewed as anecdotal. On the other hand, all of the laboratory work was done at FDA approved reference laboratories in the United States to assure statistical reliability. Gary